Sofosbuvir + Velpatasvir: Uses, Dosage, Side Effects | MedexInfo

Sofosbuvir + Velpatasvir

Rx

Generic NameSofosbuvir + Velpatasvir

Therapeutic ClassDirect-acting antiviral (DAA) combination

Common Strength400 mg / 100 mg tablet

PregnancyUse only if clearly needed

Indications ▼

Chronic hepatitis C virus (HCV) infection, genotypes 1–6

Used in adults and adolescents ≥12 years in combination therapy

Effective in patients with or without compensated cirrhosis

Mechanism & Pharmacokinetics ▼

Mechanism: Sofosbuvir: NS5B RNA polymerase inhibitor causing chain termination; Velpatasvir: NS5A inhibitor preventing viral replication and assembly. Combination halts HCV replication.

Pharmacokinetics: Rapid oral absorption; Sofosbuvir metabolized to active triphosphate (half-life ~27h); Velpatasvir reaches peak plasma ~3h; mainly excreted in feces. Co-administration enhances sustained virologic response (SVR).

Dosage & Administration ▼

Dosage must follow physician guidance, adjusted by genotype, liver function, and treatment history.

Indication / Patient Group	Dose	Frequency / Notes
Chronic HCV (all genotypes, without cirrhosis)	400 mg Sofosbuvir + 100 mg Velpatasvir	Once daily for 12 weeks
Chronic HCV with compensated cirrhosis	400 mg Sofosbuvir + 100 mg Velpatasvir	Once daily for 12 weeks (may vary in special populations)
Patients with prior DAA treatment failure	400 mg Sofosbuvir + 100 mg Velpatasvir	Once daily for 12–24 weeks per physician guidance

Side Effects ▼

Fatigue, headache, nausea

Insomnia, dizziness

Anemia when combined with ribavirin

Rare hypersensitivity reactions

Contraindications ▼

Hypersensitivity to sofosbuvir, velpatasvir, or any excipient

Concomitant use with strong P-gp inducers (may reduce efficacy)

Drug Interaction ▼

Amiodarone: risk of symptomatic bradycardia

Strong P-gp inducers (rifampin, St. John’s Wort) reduce plasma levels

Other DAAs: standard combination; monitor liver function

Pregnancy & Lactation ▼

Use only if clearly needed; consult physician

Breastfeeding safety not established; weigh risk vs. benefit

Clinical / Research Summary ▼

Clinical Role: Pan-genotypic DAA combination; first-line therapy for HCV cure.

Advantage: High sustained virologic response (SVR) across genotypes; oral once-daily dosing.

Limitation: Cost and availability may limit use in some regions; must avoid certain drug interactions.

Monitoring: Liver function, HCV RNA viral load, renal function if comorbidities exist.

Patient Counseling Points ▼

Take exactly as prescribed, once daily

Do not skip doses; complete the full course

Report fatigue, jaundice, or severe nausea promptly

Consult physician before starting new medications or supplements

Storage & Handling ▼

Store below 30°C

Protect from moisture and light

Keep out of reach of children

Brand Names (Bangladesh & Global) ▼

Bangladesh:

Panovir 400 mg + 100 mg Sofosvel 400 mg + 100 mg Tablet Fixvel 400 mg + 100 mg Tablet Hopso‑VL 400 mg + 100 mg Tablet Sovel 400 mg + 100 mg Tablet VelataS 400 mg + 100 mg Tablet Velpacee 400 mg + 100 mg Tablet Velpanex 400 mg + 100 mg Tablet Velsovir 400 mg + 100 mg Tablet

Global:

Epclusa®

Medical Disclaimer: For educational purposes only. Not a substitute for professional medical advice.

Reference Hubs:

• Drug Class: Direct-acting antivirals (DAA) • Condition: Hepatitis C Virus (HCV) Infection